Logo image of FBRX

FORTE BIOSCIENCES INC (FBRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FBRX - US34962G2084 - Common Stock

19.08 USD
-0.91 (-4.55%)
Last: 11/26/2025, 8:00:01 PM
19.08 USD
0 (0%)
After Hours: 11/26/2025, 8:00:01 PM
Fundamental Rating

3

FBRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. FBRX has a great financial health rating, but its profitability evaluates not so good. FBRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FBRX had negative earnings in the past year.
In the past year FBRX has reported a negative cash flow from operations.
FBRX had negative earnings in each of the past 5 years.
In the past 5 years FBRX always reported negative operating cash flow.
FBRX Yearly Net Income VS EBIT VS OCF VS FCFFBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

FBRX's Return On Assets of -39.38% is fine compared to the rest of the industry. FBRX outperforms 60.23% of its industry peers.
With a decent Return On Equity value of -43.05%, FBRX is doing good in the industry, outperforming 69.79% of the companies in the same industry.
Industry RankSector Rank
ROA -39.38%
ROE -43.05%
ROIC N/A
ROA(3y)-56.48%
ROA(5y)-59.11%
ROE(3y)-63.42%
ROE(5y)-64.27%
ROIC(3y)N/A
ROIC(5y)N/A
FBRX Yearly ROA, ROE, ROICFBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

FBRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FBRX Yearly Profit, Operating, Gross MarginsFBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, FBRX has more shares outstanding
Compared to 5 years ago, FBRX has more shares outstanding
FBRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FBRX Yearly Shares OutstandingFBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FBRX Yearly Total Debt VS Total AssetsFBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

FBRX has an Altman-Z score of 12.93. This indicates that FBRX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 12.93, FBRX belongs to the best of the industry, outperforming 85.55% of the companies in the same industry.
There is no outstanding debt for FBRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.93
ROIC/WACCN/A
WACCN/A
FBRX Yearly LT Debt VS Equity VS FCFFBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 11.74 indicates that FBRX has no problem at all paying its short term obligations.
FBRX has a better Current ratio (11.74) than 86.49% of its industry peers.
A Quick Ratio of 11.74 indicates that FBRX has no problem at all paying its short term obligations.
FBRX has a Quick ratio of 11.74. This is amongst the best in the industry. FBRX outperforms 86.49% of its industry peers.
Industry RankSector Rank
Current Ratio 11.74
Quick Ratio 11.74
FBRX Yearly Current Assets VS Current LiabilitesFBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

FBRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.06%, which is quite impressive.
EPS 1Y (TTM)71.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.12% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.51%
EPS Next 2Y33.75%
EPS Next 3Y21.82%
EPS Next 5Y11.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FBRX Yearly Revenue VS EstimatesFBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2028 2029 2030 2031 2032 200M 400M 600M
FBRX Yearly EPS VS EstimatesFBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBRX. In the last year negative earnings were reported.
Also next year FBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBRX Price Earnings VS Forward Price EarningsFBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBRX Per share dataFBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as FBRX's earnings are expected to grow with 21.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.75%
EPS Next 3Y21.82%

More info and screens

0

5. Dividend

5.1 Amount

FBRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTE BIOSCIENCES INC

NASDAQ:FBRX (11/26/2025, 8:00:01 PM)

After market: 19.08 0 (0%)

19.08

-0.91 (-4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-26 2026-03-26/amc
Inst Owners75.29%
Inst Owner Change5.48%
Ins Owners0.98%
Ins Owner Change0.54%
Market Cap237.16M
Revenue(TTM)N/A
Net Income(TTM)-42.45M
Analysts83.64
Price Target53.3 (179.35%)
Short Float %4.48%
Short Ratio5.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.18%
Min EPS beat(2)-41.38%
Max EPS beat(2)15.02%
EPS beat(4)3
Avg EPS beat(4)9.43%
Min EPS beat(4)-41.38%
Max EPS beat(4)37.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)16.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.41
P/tB 2.41
EV/EBITDA N/A
EPS(TTM)-5.77
EYN/A
EPS(NY)-3.74
Fwd EYN/A
FCF(TTM)-3.08
FCFYN/A
OCF(TTM)-3.07
OCFYN/A
SpS0
BVpS7.93
TBVpS7.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.38%
ROE -43.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.48%
ROA(5y)-59.11%
ROE(3y)-63.42%
ROE(5y)-64.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 187.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.74
Quick Ratio 11.74
Altman-Z 12.93
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.19%
EPS Next Y74.51%
EPS Next 2Y33.75%
EPS Next 3Y21.82%
EPS Next 5Y11.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-145.88%
OCF growth 3YN/A
OCF growth 5YN/A

FORTE BIOSCIENCES INC / FBRX FAQ

Can you provide the ChartMill fundamental rating for FORTE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to FBRX.


What is the valuation status of FORTE BIOSCIENCES INC (FBRX) stock?

ChartMill assigns a valuation rating of 1 / 10 to FORTE BIOSCIENCES INC (FBRX). This can be considered as Overvalued.


What is the profitability of FBRX stock?

FORTE BIOSCIENCES INC (FBRX) has a profitability rating of 1 / 10.